10-Q: Rezolute Inc. Reports Q2 2024 Financial Results and Provides Clinical Program Updates

Rezolute Inc. reports a net loss of $28.4 million for the six months ended December 31, 2023, while advancing its clinical programs for RZ358 and RZ402.

Summary

• Rezolute Inc., a clinical-stage biopharmaceutical company, reported a net loss of $28.4 million for the six months ended December 31, 2023, compared to a net loss of $23.4 million for the same period in 2022.
• The company's research and development expenses increased to $24.3 million for the six months ended December 31, 2023, up from $18.6 million in the prior year, primarily due to increased spending on the RZ358 program.
• General and administrative expenses also increased to $6.9 million for the six months ended December 31, 2023, compared to $6.0 million in the prior year.
• Interest and other income increased to $2.7 million for the six months ended December 31, 2023, compared to $1.3 million in the prior year, due to higher interest rates on marketable debt securities.
• As of December 31, 2023, Rezolute had cash and cash equivalents of $12.5 million and short-term investments in marketable debt securities of $80.1 million.
• The company is progressing its Phase 3 clinical trial for RZ358 in congenital hyperinsulinism (cHI) and expects to complete enrollment by the end of 2024.
• Rezolute is also conducting a Phase 2 study for RZ402 in diabetic macular edema (DME) with topline results expected in the second quarter of 2024.
• The company has an at-the-market offering agreement in place to sell up to $50 million in common stock, but no shares have been sold under this agreement as of December 31, 2023.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the company is making progress with its clinical programs and has secured an at-the-market offering, it is also facing financial losses, increased expenses, and regulatory hurdles. The partial clinical holds in the U.S. are a significant concern, and the company's ability to raise additional capital is uncertain. The sentiment is neutral to slightly negative.

Positives

• The company is actively progressing its Phase 3 clinical trial for RZ358 in cHI.
• The Phase 2 study for RZ402 in DME is on track with topline results expected soon.
• Rezolute has secured an at-the-market offering agreement for potential capital raising.
• Interest income has increased due to strategic investments in marketable debt securities.
• The company has received positive feedback from the FDA regarding RZ358 for tumor-associated hyperinsulinism (taHI) and is evaluating a potential registrational study.

Negatives

• The company reported a net loss of $28.4 million for the six months ended December 31, 2023.
• Research and development expenses have increased significantly.
• The company is subject to partial clinical holds in the U.S. for RZ358, impacting the sunRIZE study.
• Rezolute has not generated any revenue and is reliant on external financing.
• The company has significant long-term contractual obligations related to licensing agreements.

Risks

• The company is subject to partial clinical holds in the U.S. for RZ358, which could delay or prevent the inclusion of U.S. patients in the sunRIZE study.
• There is no guarantee that the company will be able to obtain additional financing to fund its long-term capital requirements.
• The company is dependent on the success of its clinical trials and regulatory approvals for its product candidates.
• The company has significant milestone payment obligations under its license agreements.
• The company's common stock may be delisted from Nasdaq if it does not regain compliance with the minimum bid price rule by May 20, 2024.

Future Outlook

The company expects to complete enrollment in the Phase 3 sunRIZE study by the end of 2024 and announce topline results in mid-2025. Topline results for the Phase 2 study of RZ402 are expected in the second quarter of 2024. The company is also evaluating a potential registrational study for RZ358 in taHI.

Management Comments

• Management believes the company's existing cash and investments will be adequate to meet contractual obligations and carry out ongoing clinical trials through February 2025.
• Management is actively engaged with the FDA to resolve partial clinical holds on RZ358.
• Management is optimistic about the potential of RZ358 in taHI based on expanded access program results.

Industry Context

Rezolute is operating in the competitive biopharmaceutical industry, focusing on rare and chronic metabolic diseases. The company's progress with RZ358 and RZ402 is being closely watched by investors and competitors in the hyperinsulinism and diabetic macular edema spaces. The company's focus on orphan drug designations and rare pediatric disease designations highlights its strategy to address unmet medical needs.

Comparison to Industry Standards

• Rezolute's R&D spending is typical for a clinical-stage biotech company, with a significant portion allocated to advancing its lead programs, RZ358 and RZ402. Companies like BioMarin Pharmaceutical and Ultragenyx Pharmaceutical, which also focus on rare diseases, have similar R&D expenditure profiles.
• The company's cash burn rate is consistent with other companies in the clinical trial phase, and its reliance on external financing is common in the biotech sector. Companies like Agenus and Celldex Therapeutics also rely on capital raises to fund their operations.
• The partial clinical holds on RZ358 in the U.S. are a significant challenge, and the company's ability to resolve these holds will be critical for its future success. Other companies, such as Sarepta Therapeutics, have faced similar regulatory hurdles in the past.
• The company's progress with RZ402 in DME is in line with other companies developing treatments for this condition, such as Regeneron and Roche. However, the oral administration of RZ402 is a differentiating factor compared to the injectable treatments that are currently available.
• The company's expanded access program for RZ358 in taHI is a unique approach that could provide valuable clinical data and potentially accelerate the development of this indication. Other companies, such as Vertex Pharmaceuticals, have used similar programs to gather data and support regulatory submissions.

Management Changes

Related Party Transactions

• Handok and certain of its affiliates were the sole investors in the 2022 Private Placement and the Registered Direct Offering.
• The company has an exclusive license agreement with Handok for the territory of the Republic of Korea.

Stakeholder Impact

• Shareholders are impacted by the company's financial losses and the potential for dilution from the at-the-market offering.
• Employees are impacted by the company's financial performance and the need to manage costs.
• Patients with cHI and DME are impacted by the progress of the company's clinical trials and the potential for new treatment options.
• The company's suppliers and creditors are impacted by its financial stability and ability to meet its obligations.

Next Steps

• Complete enrollment in the Phase 3 sunRIZE study for RZ358 by the end of 2024.
• Announce topline results for the Phase 2 study of RZ402 in the second quarter of 2024.
• Continue to work with the FDA to resolve the partial clinical holds on RZ358.
• Evaluate a potential IND application and clinical development strategy for RZ358 in taHI.
• Potentially sell shares under the at-the-market offering agreement to raise capital.

Key Dates

Keywords

RZ358, RZ402, hyperinsulinism, diabetic macular edema, clinical trial, biopharmaceutical, Phase 3, Phase 2, FDA, Orphan Drug Designation, at-the-market offering, metabolic diseases